文献速递内脏/肾动脉与血管畸形

胰腺癌手术门静脉重建的多中心结局研究

Multi-institutional study of outcomes from portal vein reconstruction during pancreatic cancer surgery.
PubMed 文献 · J Vasc Surg · 2025-07-15

结果显示PVR安全耐久,平均随访21个月时23%的重建血管闭塞,仅4%因症状需再干预,且与修复类型无关;36个月估计生存率66%,幸存者原发通畅率78%。

要点

  • PVR在胰腺癌手术中安全耐久,但中期随访约四分之一重建血管闭塞。
  • 重建类型与闭塞无关联,原发修复未必优于补片或间置血管。
  • 仅极少数闭塞需再干预,长期通畅性可能临床意义有限。

核心结论

  • 胰腺癌手术中行PVR安全且耐久,中期随访约四分之一重建失败,但极少因临床症状需再干预。
  • 研究提示PVR长期通畅性可能临床意义不大,除感染因素外,管道或重建类型可能不影响结局。

研究设计与样本

  • 采用χ2检验与Kaplan-Meier分析评估结局。

主要发现

  • 原发修复46例(58%),牛补片22例(28%),其他静脉补片2例(3%),间置管道10例(13%)。
  • 平均随访21个月,18例重建(23%)闭塞,3例(4%)再干预,距初始手术平均6.3个月,与修复类型无关联。
  • 36个月估计生存率66%,幸存者原发通畅率78%。

关键数值与推荐

  • 术后用药:阿司匹林43例(54%)、氯吡格雷1例(1.3%)、双联抗血小板3例(4%)、抗凝17例(21%)。
  • 总体并发症包括死亡45例(56%)、肠系膜缺血1例(1.3%)、再干预1例(1.3%)。

临床怎么用

  • PVR可用于提高胰腺癌手术可切除性,重建类型选择可依术者判断与感染风险考虑。
  • 术后中期需关注重建血管闭塞,但无需为无症状闭塞常规积极再干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Portal vein reconstruction (PVR) is undertaken to enhance resectability during pancreatic cancer surgery. We hypothesize that the type of reconstructions for patients undergoing PVR may not significantly influence overall outcomes. METHODS: Patients undergoing PVR for pancreatic cancer surgery (2013-2023) were identified at three academic institutions. χ2 and Kaplan-Meier analyses were used to evaluate outcomes. RESULTS: Eighty patients were captured, with 53% men and 45% women. Preoperative chemoradiation was undertaken in 70% of patients. Pancreaticoduodenectomy was undertaken in 79 patients (92%), with distal pancreatectomy in one (1.2%). Primary repair was undertaken in 46 patients (58%), bovine patch in 22 (28%), other vein patch in two (3%), with interposition conduits such as the internal jugular vein, great saphenous vein, superficial femoral vein, and PTFE in 10 (13%). Thirty-day complications included four deaths (5%), one stroke (1.3%), and one major adverse cardiac event (1.3%). Overall complications included death in 45 patients (56%), mesenteric ischemia in one (1.3%), and reintervention in one patient (1.3%). Postoperative medications included aspirin in 43 patients (54%), clopidogrel in one (1.3%), dual antiplatelet therapy in three (4%), and anticoagulation in 17 (21%). Over 21 months mean follow-up, 18 reconstructions (23%) occluded, with three (4%) reintervened upon at a mean of 6.3 months from index procedure with no association with type of repair. At 36 months, estimated survival was 66%, of which primary patency in survivors was 78%. CONCLUSIONS: PVR during pancreatic cancer surgery is safe and durable. One-quarter of all reconstructions fail at medium-term follow-up, and very few require reintervention for clinical symptoms. Although primary repair has been suggested as the most optimal reconstruction, our findings imply that long-term patency of PVR may not be clinically important. Furthermore, outside of infectious considerations, it is likely that conduit or reconstruction type does not affect outcome.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Gondi S, McSpadden M, Schlesselman C, et al. Multi-institutional study of outcomes from portal vein reconstruction during pancreatic cancer surgery. J Vasc Surg. 2025. PMID: 40675402. doi:10.1016/j.jvs.2025.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。